Treatment of KRAS-Mutated Pancreatic Cancer: New Hope for the Patients?

Abstract excerpt

Pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDAC), ranks among the most lethal malignancies, with a 5-year survival rate of under 10%. The most prevalent KRAS mutations occur in three hotspot residues: glycine-12 (G12), glycine-13 (G13), and glutamine-61 (Q61), leading to the constant activation of the Ras pathway, making them the primary focus in oncologic drug development. Selective KRAS...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Pancreatic and Hepatic Oncology Research
• Share to Peptidase Inhibition and Analysis
• Share to Protein Degradation and Inhibitors